Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay

European Journal of Medicinal Chemistry

Volumn 61, Issue , 2013, Pages 41-48

  Rohe, Alexander ^a   Göllner, Christiane ^a   Wichapong, Kanin ^a   Erdmann, Frank ^a   Al Mazaideh, Ghassab M A ^a   Sippl, Wolfgang ^a,b   Schmidt, Matthias ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Binding assay; Docking; Inhibitor; Organic synthesis; Protein kinase Myt1

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DASATINIB; ERLOTINIB; FASUDIL; GEFITINIB; GLYCEROLIPID; IMATINIB; LAPATINIB; MIDOSTAURIN; PD 0166285; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE MYT1; STAUROSPORINE; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR DOCKING;

DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLYCOLIPIDS; HUMANS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874940962     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.06.007     Document Type: Article

References (36)

1. M. Suganuma, T. Kawabe, H. Hori, T. Funabiki, and T. Okamoto Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation Cancer Res. 59 1999 5887 5891
2. A.J. Levine p53, The cellular gatekeeper for growth and division Cell 88 1997 323 331
3. T. Kawabe G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther. 3 2004 513 519
4. J. Ptacek, G. Devgan, G. Michaud, H. Zhu, X. Zhu, J. Fasolo, H. Guo, G. Jona, A. Breitkreutz, R. Sopko, R.R. McCartney, M.C. Schmidt, N. Rachidi, S.J. Lee, A.S. Mah, L. Meng, M.J. Stark, D.F. Stern, C. De Virgilio, M. Tyers, B. Andrews, M. Gerstein, B. Schweitzer, P.F. Predki, and M. Snyder Global analysis of protein phosphorylation in yeast Nature 438 2005 679 684
5. J.A. Ubersax, E.L. Woodbury, P.N. Quang, M. Paraz, J.D. Blethrow, K. Shah, K.M. Shokat, and D.O. Morgan Targets of the cyclin-dependent kinase Cdk1 Nature 425 2003 859 864
6. A. Lindqvist, V. Rodríguez-Bravo, and R.H. Medema The decision to enter mitosis: feedback and redundancy in the mitotic entry network J. Cell Biol. 185 2009 193 202
7. S. Leijen, J.H. Beijnen, and J.H. Schellens Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents Curr. Clin. Pharmacol. 5 2010 186 191
8. J.M. Kreahling, J.Y. Gemmer, D. Reed, D. Letson, M. Bui, and S. Altiok MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells Mol. Cancer Ther. 11 2012 174 182
9. P.C. De Witt Hamer, S.E. Mir, D. Noske, C.J.F. Van Noorden, and T. Würdinger WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe Clin. Cancer Res. 17 2011 4200 4207
10. Y. Wang, S.J. Decker, and J. Sebolt-Leopold Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis Cancer Biol. Ther. 3 2004 305 313
11. C. Bruyère, S. Madonna, G.V. Goietsenoven, V. Mathieu, J. Dessolin, J.-L. Kraus, F. Lefranc, and R. Kiss JLK1486, a bis 8-hydroxyquinoline-substituted benzylamine, displays cytostatic effects in experimental gliomas through MyT1 and STAT1 activation and, to a lesser extent, PPARγ activation Transl. Oncol. 4 2011 126 137
12. P.R. Mueller, T.R. Coleman, A. Kumagai, and W.G. Dunphy Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15 Science 270 1995 86 90
13. Y. Wang, J. Li, R.N. Booher, A. Kraker, T. Lawrence, W.R. Leopold, and Y. Sun Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator Cancer Res. 61 2001 8211 8217
14. O. Hashimoto, M. Shinkawa, T. Torimura, T. Nakamura, K. Selvendiran, M. Sakamoto, H. Koga, T. Ueno, and M. Sata Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line BMC Cancer 6 2006 292
15. R.L. Panek, G.H. Lu, S.R. Klutchko, B.L. Batley, T.K. Dahring, J.M. Hamby, H. Hallak, A.M. Doherty, and J.A. Keiser In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor J. Pharmacol. Exp. Ther. 283 1997 1433 1444
16. B.-N. Zhou, S. Tang, R.K. Johnson, M.P. Mattern, J.S. Lazo, E.R. Sharlow, K. Harichd, and D.G.I. Kingston New glycolipid inhibitors of Myt1 kinase Tetrahedron 61 2005 883 887
17. A. Rohe, F. Erdmann, C. Bäßler, K. Wichapong, W. Sippl, and M. Schmidt In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase Bioorg. Med. Chem. Lett. 22 2012 1219 1223
18. C.S. Lebakken, S.M. Riddle, U. Singh, W.J. Frazee, H.C. Eliason, Y. Gao, L.J. Reichling, B.D. Marks, and K.W. Vogel Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform J. Biomol. Screen. 14 2009 924 935
19. C. Göllner, C. Philipp, B. Dobner, W. Sippl, and M. Schmidt First total synthesis of 1,2-dipalmitoyl-3-(N-palmitoyl-6′-amino-6′-deoxy- alpha-D-glucosyl)-sn-glycerol-a glycoglycerolipid of a marine alga with a high inhibitor activity against human Myt1-kinase Carbohydr. Res. 344 2009 1628 1631
20. MOE 2010.10 2010 Chemical Computing Group, Inc. Montreal, Canada
21. G. Jones, P. Willett, and R.C. Glen Molecular recognition of receptor-sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 245 1995 43 53
22. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
23. K. Wichapong, M. Lawson, S. Pianwanit, S. Kokpol, and W. Sippl Postprocessing of protein-ligand docking poses using linear response MM-PB/SA: application to Wee1 kinase inhibitors J. Chem. Inf. Model. 50 2010 1574 1588
24. K. Wichapong, M. Lindner, S. Pianwanit, S. Kokpol, and W. Sippl Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors Eur. J. Med. Chem. 44 2009 1383 1395
25. L. Munoz, R. Selig, Y.T. Yeung, C. Peifer, D. Hauser, and S. Laufer Fluorescence polarization binding assay to develop inhibitors of inactive p38 alpha mitogen-activated protein kinase Anal. Biochem. 401 2010 125 133
26. O. Hantschel, U. Rix, and G. Superti-Furga Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib Leuk. Lymph. 49 2008 615 619
27. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, and P.P. Zarrinkar Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
28. L. Stryer, D.D. Thomas, and C.F. Meares Diffusion-enhanced fluorescence energy transfer Ann. Rev. Biophys. Bioeng. 11 1982 203 222
29. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. Mathieson, J. Perrin, M. Raida, C. Rau, V. Reader, G. Sweetman, A. Bauer, T. Bouwmeester, C. Hopf, U. Kruse, G. Neubauer, N. Ramsden, J. Rick, B. Kuster, and G. Drewes Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25 2007 1035 1044
30. U. Rix, O. Hantschel, G. Dürnberger, L.L. Remsing Rix, M. Planyavsky, N.V. Fernbach, I. Kaupe, K.L. Bennett, P. Valent, J. Colinge, T. Köcher, and G. Superti-Furga Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 110 2007 4055 4063
31. T. O'Hare, D.K. Walters, E.P. Stoffregen, T. Jia, P.W. Manley, J. Mestan, S.W. Cowan-Jacob, F.Y. Lee, M.C. Heinrich, M.W.N. Deininger, and B.J. Druker In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res. 65 2005 4500 4505
32. F. Zuccotto, E. Ardini, E. Casale, and M. Angiolini Through the gatekeeper door: exploiting the active kinase conformation J. Med. Chem. 53 2010 2681 2694
33. W. Davidson, L. Frego, G.W. Peet, R.R. Kroe, M.E. Labadia, S.M. Lukas, R.J. Snow, S. Jakes, C.A. Grygon, C. Pargellis, and B.G. Werneburg Discovery and characterization of a substrate selective p38 alpha inhibitor Biochemistry US 43 2004 11658 11671
34. S.M. Lukas, R.R. Kroe, J. Wildeson, G.W. Peet, L. Frego, W. Davidson, R.H. Ingraham, C.A. Pargellis, M.E. Labadia, and B.G. Werneburg Catalysis and function of the p38 alpha circle MK2a signaling complex Biochemistry US 43 2004 9950 9960
35. N.J. Wells, N. Watanabe, T. Tokusumi, W. Jiang, M.A. Verdecia, and T. Hunter The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression J. Cell Sci. 112 1999 3361 3371
36. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, and D.C. Klenk Measurement of protein using bicinchoninic acid Anal. Biochem. 150 1985 76 85